We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+13.46%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$9.51M
Cap. Flow
-$1.26M
Cap. Flow %
-0.81%
Top 10 Hldgs %
79.2%
Holding
49
New
5
Increased
3
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$1.16M
2
GERN icon
Geron
GERN
+$1.1M
3
KYNB
Kyntra Bio
KYNB
+$463K
4
CABA icon
Cabaletta Bio
CABA
+$446K
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$312K

Top Sells

Rank Stock Value
1
MELI icon
Mercado Libre
MELI
+$1.19M
2
GTLB icon
GitLab
GTLB
+$1.12M
3
BMEA icon
Biomea Fusion
BMEA
+$626K
4
TVTX icon
Travere Therapeutics
TVTX
+$576K
5
ASND icon
Ascendis Pharma A/S
ASND
+$447K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Technology 0.23%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
26
Acadia Pharmaceuticals
ACAD
$5.03B
$718K 0.46%
29,984
– –
DBVT
27
DBV Technologies
DBVT
$847M
$705K 0.45%
37,095
– –
RYTM icon
28
Rhythm Pharmaceuticals
RYTM
$7.96B
$661K 0.42%
40,070
+7,550
+23% +$136K
ARGX icon
29
argenx
ARGX
$54.1B
$557K 0.36%
1,430
– –
CABA icon
30
Cabaletta Bio
CABA
$455M
$531K 0.34%
+41,123
New +$446K
GTLB icon
31
GitLab
GTLB
$6.58B
$353K 0.23%
6,910
-30,042
-81% -$1.12M
RETA
32
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$336K 0.22%
+3,300
New +$312K
ALXO icon
33
ALX Oncology
ALXO
$290M
$315K 0.2%
41,950
– –
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$12.4B
$313K 0.2%
3,615
-3,600
-50% -$339K
MDGL icon
35
Madrigal Pharmaceuticals
MDGL
$11.8B
$273K 0.17%
1,182
– –
AFMD
36
DELISTED
Affimed
AFMD
$223K 0.14%
37,247
– –
AKRO
37
DELISTED
Akero Therapeutics
AKRO
$207K 0.13%
+4,425
New +$203K
KYNB
38
Kyntra Bio
KYNB
$29.4M
$168K 0.11%
2,484
+1,120
+82% +$463K
KOD icon
39
Kodiak Sciences
KOD
$2.84B
$135K 0.09%
19,622
– –
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.4B
$126K 0.08%
17,847
– –
ABCL icon
41
AbCellera Biologics
ABCL
$2.12B
$80.9K 0.05%
12,521
– –
CERS icon
42
Cerus
CERS
$474M
$34.9K 0.02%
14,172
– –
LONA
43
LeonaBio Inc
LONA
$72.1M
$34.7K 0.02%
+1,177
New +$33.5K
ASND icon
44
Ascendis Pharma A/S
ASND
$16.8B
– –
-4,168
Closed -$447K
MELI icon
45
Mercado Libre
MELI
$92.3B
– –
-904
Closed -$1.19M
NRIX icon
46
Nurix Therapeutics
NRIX
$2.65B
– –
-11,500
Closed -$102K
TVTX icon
47
Travere Therapeutics
TVTX
$5.78B
– –
-25,606
Closed -$576K
NVTA
48
DELISTED
Invitae Corporation
NVTA
– –
-11,337
Closed -$15.3K
STSA
49
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-177,900
Closed -$124K
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q2 2023 Portfolio in Review

As of Q2 2023, Nan Fung Group Holdings held 49 positions worth $156M, up 6.5% from $147M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Nan Fung Group Holdings's Q2 2023 filing shows 5 new, 3 increased, 6 reduced and 6 closed positions. Its largest new stake was Geron: 388,000 shares worth $1.25M. The largest sale was Mercado Libre, an estimated $1.19M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Nan Fung Group Holdings's largest Q2 2023 buy was Geron: 388,000 shares worth $1.25M.
  • Nan Fung Group Holdings added most to KalVista Pharmaceuticals in Q2 2023, an estimated $1.16M increase.
  • Nan Fung Group Holdings's biggest Q2 2023 reduction was GitLab, cutting an estimated $1.12M.
  • Nan Fung Group Holdings fully exited Mercado Libre in Q2 2023, selling an estimated $1.19M.
  • Nan Fung Group Holdings's ten largest holdings make up 79% of its $156M portfolio in Q2 2023.
  • Nan Fung Group Holdings opened 5 new positions and closed 6 in Q2 2023.
  • Nan Fung Group Holdings's portfolio value rose 6.5% quarter-over-quarter to $156M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.